- Home
- RANI vs SLAI Comparison
RANI vs SLAI Comparison
Compare RANI & SLAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- SLAI
- Stock Information
- Founded
- RANI 2012
- SLAI 2001
- Country
- RANI United States
- SLAI United States
- Employees
- RANI N/A
- SLAI N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- SLAI EDP Services
- Sector
- RANI Health Care
- SLAI Technology
- Exchange
- RANI Nasdaq
- SLAI Nasdaq
- Market Cap
- RANI 24.2M
- SLAI 23.1M
- IPO Year
- RANI 2021
- SLAI N/A
- Fundamental
- Price
- RANI $2.12
- SLAI $2.41
- Analyst Decision
- RANI Strong Buy
- SLAI
- Analyst Count
- RANI 6
- SLAI 0
- Target Price
- RANI $8.67
- SLAI N/A
- AVG Volume (30 Days)
- RANI 44.1M
- SLAI 393.8K
- Earning Date
- RANI 11-13-2025
- SLAI 11-19-2025
- Dividend Yield
- RANI N/A
- SLAI N/A
- EPS Growth
- RANI N/A
- SLAI N/A
- EPS
- RANI N/A
- SLAI N/A
- Revenue
- RANI $1,200,000.00
- SLAI $24,576,000.00
- Revenue This Year
- RANI N/A
- SLAI N/A
- Revenue Next Year
- RANI N/A
- SLAI N/A
- P/E Ratio
- RANI N/A
- SLAI N/A
- Revenue Growth
- RANI N/A
- SLAI N/A
- 52 Week Low
- RANI $0.39
- SLAI $1.22
- 52 Week High
- RANI $3.87
- SLAI $8.07
- Technical
- Relative Strength Index (RSI)
- RANI 65.39
- SLAI N/A
- Support Level
- RANI $1.76
- SLAI N/A
- Resistance Level
- RANI $3.87
- SLAI N/A
- Average True Range (ATR)
- RANI 0.45
- SLAI 0.00
- MACD
- RANI 0.14
- SLAI 0.00
- Stochastic Oscillator
- RANI 45.98
- SLAI 0.00
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.